<DOC>
	<DOCNO>NCT01271920</DOCNO>
	<brief_summary>The phase Ib part trial ass MTD AUY922 combination Trastuzumab patient Trastuzumab-refractory locally advance metastatic HER2+ . The MTD define high drug dosage cause first cycle treatment ( 28 day ) medically unacceptable dose limit toxicity ( DLT ) . The phase II part trial ass potential effect efficacy add AUY922 Trastuzumab patient Trastuzumab-refractory locally advance metastatic HER2+ breast cancer . Both AUY922 Trastuzumab administer weekly IV infusion . Treatment continue long patient disease progression tolerate treatment . The following reason examples acceptable reason discontinue study ; tumor progression ( RECIST , assess investigator ) , unacceptable toxicity , death , discontinuation study reason , patient refusal , withdrawn consent , lose follow-up investigator decision .</brief_summary>
	<brief_title>Combination AUY922 With Trastuzumab HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient confirm HER2 positive , nonoperable locally advanced metastatic breast cancer All patient must receive least 1 2 prior anti HER2 base regimen include least 1 regimen contain Trastuzumab . All patient must least one measurable lesion define RECIST criterion . All patient must document progressive disease follow last line therapy enter study ECOG Performance status â‰¤ 1 Patients know CNS metastasis : symptomatic require treatment symptom control and/or grow Prior treatment HSP90 HDAC inhibitor Impaired cardiac function Acute chronic liver renal disease Patients currently receive treatment medication relative risk prolong QTc interval induce Torsades de Pointes switch discontinue alternative drug prior commence AUY922 Patients history another primary malignancy currently clinically significant currently require active intervention Patients either archival tumor sample available unwilling fresh tumor sample collect baseline . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Trastuzumab-refractory</keyword>
	<keyword>advanced HER2-positive breast cancer ,</keyword>
	<keyword>Hsp90 ,</keyword>
	<keyword>2nd 3rd line treatment</keyword>
</DOC>